Tg Therapeutics (TGTX) Operating Margin (2017 - 2026)
Tg Therapeutics (TGTX) recorded quarterly Operating Margin of 16.98% in Q1 2026, down 35.24% quarter-over-quarter from 26.22% in Q4 2025, and up 985.0% on a YoY basis from 1.56% in Q1 2025.
Tg Therapeutics (TGTX) Operating Margin (2017 - 2026) Analysis & Trends
Tg Therapeutics' Operating Margin history runs 10 years deep, the most recent figure standing at 16.98% for Q1 2026.
- In Q1 2026, Operating Margin rose 985.0% year-over-year to 16.98%; the TTM figure through Mar 2026 stood at 21.35% (up 586.0% YoY), while the FY2025 annual figure was 20.01%, up 727.0% from the prior year.
- Operating Margin was 16.98% for Q1 2026 at Tg Therapeutics, down from 26.22% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 69.22% in Q3 2023 to a low of 96923.75% in Q4 2022.
- Historically, Operating Margin has averaged 8506.47% across 5 years, with a median of 7.13% in 2025.
- The sharpest annual moves came in 2022 and 2023: Operating Margin slumped 9291914 bps in 2022, then surged 9685467 bps in 2023.
- A 5-year view of Operating Margin shows it stood at 96923.75% in 2022, then surged by 100 bps to 69.08% in 2023, then jumped by 140 bps to 27.68% in 2024, then fell by 5 bps to 26.22% in 2025, then plunged by 35 bps to 16.98% in 2026.
- The last three Operating Margin figures came in at 16.98% (Q1 2026), 26.22% (Q4 2025), and 18.16% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tg Therapeutics | 7.71 Bn | 7.06 Bn | 171.41 Mn | 16.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.98% |
| Dec 31, 2025 | 26.22% |
| Sep 30, 2025 | 18.16% |
| Jun 30, 2025 | 24.69% |
| Mar 31, 2025 | 7.13% |
| Dec 31, 2024 | 27.68% |
| Sep 30, 2024 | 14.82% |
| Jun 30, 2024 | 12.00% |
| Mar 31, 2024 | -14.60% |
| Dec 31, 2023 | -69.08% |
| Sep 30, 2023 | 69.22% |
| Jun 30, 2023 | -277.93% |
| Mar 31, 2023 | -474.07% |
| Dec 31, 2022 | -96,923.75% |
| Sep 30, 2022 | -37,194.68% |
| Jun 30, 2022 | -6,555.72% |
| Mar 31, 2022 | -3,317.06% |
| Dec 31, 2021 | -4,004.61% |
| Sep 30, 2021 | -4,193.50% |
| Jun 30, 2021 | -5,015.66% |